thiotepa has been researched along with Infection in 10 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Toxicity included mostly infections." | 2.75 | Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. ( Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL, 2010) |
| "Women with stage IV breast cancer who had achieved a CR or PR during conventional chemotherapy were enrolled in a phase II trial of high-dose cyclophosphamide 7500 mg/m2 and thiotepa 675 mg/m2 (C+T) followed within 180 days by high-dose melphalan (M) 140 mg/m2." | 2.68 | Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. ( Bitran, JD; Hanauer, S; Harris, E; Johnson, L; Kempler, J; Klein, L; Martinec, J; Samuels, B; White, W, 1996) |
| " The toxic death rate was 1%." | 1.32 | Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. ( Baars, JW; Holtkamp, MJ; Rodenhuis, S; Schornagel, JH; Schrama, JG, 2003) |
| "The median time to disease progression and median survival were 1." | 1.31 | Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. ( Blume, KG; Chao, NJ; Feiner, RH; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Wong, RM, 2000) |
| "As compared with metastatic breast cancer (MBC), high risk breast cancer showed a 2." | 1.31 | Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. ( Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreri, AJ | 1 |
| Cwynarski, K | 1 |
| Pulczynski, E | 1 |
| Ponzoni, M | 1 |
| Deckert, M | 1 |
| Politi, LS | 1 |
| Torri, V | 1 |
| Fox, CP | 1 |
| Rosée, PL | 1 |
| Schorb, E | 1 |
| Ambrosetti, A | 1 |
| Roth, A | 1 |
| Hemmaway, C | 1 |
| Ferrari, A | 1 |
| Linton, KM | 1 |
| Rudà, R | 1 |
| Binder, M | 1 |
| Pukrop, T | 1 |
| Balzarotti, M | 1 |
| Fabbri, A | 1 |
| Johnson, P | 1 |
| Gørløv, JS | 1 |
| Hess, G | 1 |
| Panse, J | 1 |
| Pisani, F | 1 |
| Tucci, A | 1 |
| Stilgenbauer, S | 1 |
| Hertenstein, B | 1 |
| Keller, U | 1 |
| Krause, SW | 1 |
| Levis, A | 1 |
| Schmoll, HJ | 1 |
| Cavalli, F | 1 |
| Finke, J | 1 |
| Reni, M | 1 |
| Zucca, E | 1 |
| Illerhaus, G | 1 |
| Ciurea, SO | 1 |
| Saliba, R | 1 |
| Rondon, G | 1 |
| Pesoa, S | 1 |
| Cano, P | 1 |
| Fernandez-Vina, M | 1 |
| Qureshi, S | 1 |
| Worth, LL | 1 |
| McMannis, J | 1 |
| Kebriaei, P | 1 |
| Jones, RB | 1 |
| Korbling, M | 1 |
| Qazilbash, M | 1 |
| Shpall, EJ | 1 |
| Giralt, S | 1 |
| de Lima, M | 1 |
| Champlin, RE | 1 |
| Gajewski, J | 1 |
| Schrama, JG | 1 |
| Holtkamp, MJ | 1 |
| Baars, JW | 1 |
| Schornagel, JH | 1 |
| Rodenhuis, S | 1 |
| Bitran, JD | 1 |
| Samuels, B | 1 |
| Klein, L | 1 |
| Hanauer, S | 1 |
| Johnson, L | 1 |
| Martinec, J | 1 |
| Harris, E | 1 |
| Kempler, J | 1 |
| White, W | 1 |
| Bacigalupo, A | 1 |
| Van Lint, MT | 1 |
| Valbonesi, M | 1 |
| Lercari, G | 1 |
| Carlier, P | 1 |
| Lamparelli, T | 1 |
| Gualandi, F | 1 |
| Occhini, D | 1 |
| Bregante, S | 1 |
| Valeriani, A | 1 |
| Piaggio, G | 1 |
| Pitto, A | 1 |
| Benvenuto, F | 1 |
| Figari, O | 1 |
| De Stefano, G | 1 |
| Caimo, A | 1 |
| Sessarego, M | 1 |
| Hu, WW | 1 |
| Negrin, RS | 1 |
| Stockerl-Goldstein, K | 1 |
| Johnston, LJ | 1 |
| Shizuru, JA | 1 |
| Wong, RM | 1 |
| Chao, NJ | 1 |
| Long, GD | 1 |
| Feiner, RH | 1 |
| Blume, KG | 1 |
| Morabito, F | 1 |
| Irrera, G | 1 |
| Oliva, E | 1 |
| Console, G | 1 |
| Martino, M | 1 |
| Pucci, G | 1 |
| Messina, G | 1 |
| Barbaro, P | 1 |
| Palazzo, S | 1 |
| Iacopino, P | 1 |
| Saarinen, UM | 1 |
| Hovi, L | 1 |
| Mäkipernaa, A | 1 |
| Riikonen, P | 1 |
| Kottmeier, HL | 1 |
| Saslaw, S | 1 |
| Carlisle, HN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Tra[NCT01011920] | Phase 2 | 126 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Prospective Randomized Feasibility and Phase II Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors.[NCT00851110] | Phase 2 | 50 participants (Anticipated) | Interventional | 2004-10-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thiotepa and Infection
| Article | Year |
|---|---|
Treatment of ovarian cancer with thiotepa.
Topics: Bone Marrow Diseases; Female; Humans; Infections; Injections, Intravenous; Ovarian Neoplasms; Pallia | 1968 |
4 trials available for thiotepa and Infection
| Article | Year |
|---|---|
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Topics: Acute Kidney Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System | 2016 |
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Ce | 2010 |
Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1996 |
Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone M | 1996 |
5 other studies available for thiotepa and Infection
| Article | Year |
|---|---|
Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carboplatin; C | 2003 |
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
Topics: Adjuvants, Pharmaceutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; B | 2000 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplast | 2001 |
High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors.
Topics: Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Evaluat | 1991 |
Nonhuman primates in evaluation of hematotoxicity.
Topics: Animals; Busulfan; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug-Related Side Effects and Adver | 1969 |